J2506 HCPCS code: Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
J2506 is the HCPCS Level II code for injection, pegfilgrastim, excludes biosimilar, 0.5 mg. In 2024 Medicare paid an average of $51.76 per service for J2506 across 138,840 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 12 per day on outpatient hospital claims. Medicare volume fell 80% from 2022 to 2024 (711,755 to 138,840 services). In 2024, about 1,844 clinicians billed Medicare for J2506 for 4,043 beneficiaries; Texas, California, Virginia accounted for 44% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2022-01-01 |
| Last action effective | 2023-04-01 |
Who bills J2506 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,844 |
| Medicare beneficiaries | 4,043 |
| States with claims | 31 |
| Share of services in top 3 states (Texas, California, Virginia) | 44% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J2506, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 711,755 | 16,141 | $156.81 | $125.17 |
| 2023 | 533,301 | 12,209 | $101.51 | $80.81 |
| 2024 | 138,840 | 4,043 | $65.22 | $51.76 |
States with the most J2506 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 27,110 | $59.60 |
| California | 21,238 | $45.56 |
| Virginia | 11,160 | $59.45 |
| Illinois | 10,024 | $54.78 |
| Colorado | 7,284 | $49.82 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 12 | Prescribing Information |
| practitioner claims | 12 | Prescribing Information |
Medicare policy articles for this code
- A54682: Billing and Coding: Neulasta® (pegfilgrastim) Onpro® Kit / UDENYCA® ONBODY™ (On-body Injector) (Palmetto GBA (MAC - Part A, MAC - Part B))
- A56748: Billing and Coding: White Cell Colony Stimulating Factors (Palmetto GBA (MAC - Part A, MAC - Part B))
- A59126: Pegfilgrastim (Fulphila; Neulasta; Neulasta Onpro; Nyvepria; Udenyca; Ziextenzo) J2506 (CGS Administrators, LLC (MAC - Part A, MAC - Part B))
- A59661: Pegfilgrastim (Fulphila; Neulasta; Neulasta Onpro; Nyvepria; Udenyca; Ziextenzo) J2506 (Wellpoint Federal (MAC - Part A, MAC - Part B))
Covered diagnoses (1,265 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| B20 | Human immunodeficiency virus [HIV] disease | 1 |
| C00.0 | Malignant neoplasm of external upper lip | 1 |
| C00.1 | Malignant neoplasm of external lower lip | 1 |
| C00.2 | Malignant neoplasm of external lip, unspecified | 1 |
| C00.3 | Malignant neoplasm of upper lip, inner aspect | 1 |
| C00.4 | Malignant neoplasm of lower lip, inner aspect | 1 |
| C00.5 | Malignant neoplasm of lip, unspecified, inner aspect | 1 |
| C00.6 | Malignant neoplasm of commissure of lip, unspecified | 1 |
| C00.8 | Malignant neoplasm of overlapping sites of lip | 1 |
| C00.9 | Malignant neoplasm of lip, unspecified | 1 |
Showing 10 of 1,265. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J2506
- 2022-01-01: J2506 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2506?
J2506 is the HCPCS Level II code for injection, pegfilgrastim, excludes biosimilar, 0.5 mg. Short descriptor: "Inj pegfilgrast ex bio 0.5mg".
How much does Medicare pay for J2506?
In 2024, the average Medicare payment was $51.76 per service (average allowed $65.22).
Does Medicare cover J2506?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J2506?
Medicare policy articles that cite J2506 list 1,265 covered ICD-10-CM diagnosis codes across 4 articles. The most cited include B20 (Human immunodeficiency virus [HIV] disease), C00.0 (Malignant neoplasm of external upper lip), C00.1 (Malignant neoplasm of external lower lip). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J2506 can be billed per day?
12 on outpatient hospital claims; 12 on practitioner claims (NCCI medically unlikely edits).
Related J25 codes
- J2501 — Injection, paricalcitol, 1 mcg
- J2502 — Injection, pasireotide long acting, 1 mg
- J2503 — Injection, pegaptanib sodium, 0.3 mg
- J2504 — Injection, pegademase bovine, 25 iu
- J2505 — Injection, pegfilgrastim, 6 mg
- J2507 — Injection, pegloticase, 1 mg
- J2508 — Injection, pegunigalsidase alfa-iwxj, 1 mg
- J2510 — Injection, penicillin g procaine, aqueous, up to 600,000 units
- J2513 — Injection, pentastarch, 10% solution, 100 ml
- J2515 — Injection, pentobarbital sodium, per 50 mg
- J2516 — Injection, pentamidine isethionate, 1 mg
- J2540 — Injection, penicillin g potassium, up to 600,000 units
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2506
- Watch J2506 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2506
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.